Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/12/16 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
50 | |
| 12/12/16 | 8-K | Current report filing |
|
61 | |
| 12/12/16 | 8-K | Current report filing |
|
3 | |
| 11/21/16 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 10/21/16 | EFFECT | Notice of Effectiveness |
|
1 | |
| 10/21/16 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/21/16 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
35 | |
| 10/19/16 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 10/19/16 | S-3/A | Registration statement for specified transactions by certain issuers |
|
46 | |
| 10/17/16 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
